Performance of Dark Chemical Matter in High Throughput Screening.
暂无分享,去创建一个
[1] Anne Mai Wassermann,et al. Dark chemical matter as a promising starting point for drug lead discovery. , 2015, Nature chemical biology.
[2] Stefan Schmitt,et al. Stratified High-Throughput Screening Sets Enable Flexible Screening Strategies from a Single Plated Collection , 2014, Journal of biomolecular screening.
[3] D. Pereira,et al. Origin and evolution of high throughput screening , 2007, British journal of pharmacology.
[4] W. Guida,et al. The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.
[5] Andrew Bell,et al. Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy , 2012, J. Chem. Inf. Model..
[6] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[7] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[8] Dragos Horvath,et al. Design of a General‐Purpose European Compound Screening Library for EU‐OPENSCREEN , 2014, ChemMedChem.
[9] Gregory A. Bakken,et al. A Heuristic Algorithm for Plate SelectionThat Maximizes Compound Diversity , 2013 .
[10] Andreas Bender,et al. “Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection , 2007, Journal of biomolecular screening.
[11] Anne Mai Wassermann,et al. Biodiversity of small molecules--a new perspective in screening set selection. , 2013, Drug discovery today.
[12] Thorsten Nowak,et al. Expanding medicinal chemistry space. , 2013, Drug discovery today.
[13] R. Spencer,et al. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. , 1998, Biotechnology and bioengineering.
[14] S. P. Fodor,et al. Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. , 1994, Journal of medicinal chemistry.
[15] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[16] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[17] Anil Vasudevan,et al. Abbott Physicochemical Tiering (APT)--a unified approach to HTS triage. , 2012, Bioorganic & medicinal chemistry.
[18] Jérôme Hert,et al. Quantifying Biogenic Bias in Screening Libraries , 2009, Nature chemical biology.
[19] Tudor I. Oprea,et al. The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.
[20] D. Bojanic,et al. Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.
[21] I. Muegge. Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.